Get the Stockscreener App
1.97
0.51%
-0.01
Genelux Corp stock is traded at $1.97, with a volume of 127.97K.
It is down -0.51% in the last 24 hours and down -21.67% over the past month.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
See More
Previous Close:
$1.98
Open:
$2.02
24h Volume:
127.97K
Relative Volume:
0.31
Market Cap:
$89.13M
Revenue:
$8,000
Net Income/Loss:
$-33.58M
P/E Ratio:
-2.3076
EPS:
-0.8537
Net Cash Flow:
$-27.88M
1W Performance:
-18.60%
1M Performance:
-21.67%
6M Performance:
-21.83%
1Y Performance:
-74.45%
1-Day Range:
$1.90
$2.07
1-Week Range:
$1.96
$2.6121
52-Week Range:
$1.90
$8.535
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
805-267-9889
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
1.97 | 89.13M | 8,000 | -33.58M | -27.88M | -0.8537 |
VRTX
Vertex Pharmaceuticals Inc
|
525.63 | 133.23B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
808.80 | 83.27B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
205.71 | 82.12B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
879.53 | 55.31B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
375.74 | 42.50B | 5.76B | 514.49M | 1.10B | 4.4813 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Lake Street | Buy |
| Oct-29-24 | Initiated | Guggenheim | Buy |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Nov-27-23 | Initiated | H.C. Wainwright | Buy |
| Sep-12-23 | Initiated | Maxim Group | Buy |
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
View All
Genelux Corp Stock (GNLX) Latest News
Genelux Corporation Common Stock (NASDAQ: GNLX) Stock Price, News & Analysis - kalkine.com.au
Genelux CorporationCommon Stock (Nasdaq:GNLX) Stock Quote - The Chronicle-Journal
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy - Yahoo Finance
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Genelux chief scientific officer Yu Yong sells $26,658 of stock By Investing.com - Investing.com South Africa
Genelux Corporation Common Stock (NASDAQ: GNLX) Stock Price, News & Analysis - kalkine.ca
Genelux chief scientific officer Yu Yong sells $26,658 of stock By Investing.com - Investing.com Canada
Genelux CTO Joseph Cappello sells $28,112 in company stock By Investing.com - Investing.com Nigeria
Genelux CEO Zindrick sells $91,899 in common stock - Investing.com India
Genelux CEO Zindrick sells $91,899 in common stock - Investing.com
Genelux CTO Joseph Cappello sells $28,112 in company stock - Investing.com
Genelux CTO Joseph Cappello sells $28,112 in company stock By Investing.com - Investing.com Canada
Genelux chief scientific officer Yu Yong sells $26,658 of stock By Investing.com - Investing.com UK
Genelux chief scientific officer Yu Yong sells $26,658 of stock - investing.com
Benchmark reiterates Genelux stock rating on cancer therapy progress - Investing.com
Benchmark reiterates Genelux stock rating on cancer therapy progress - Investing.com
Equities Analysts Offer Predictions for Genelux Q3 Earnings - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Auxly Cannabis Group (CBWTD), Genelux Corp. (GNLX) - The Globe and Mail
Genelux: Undervalued Oncolytic Virus Leader as Olvi-Vec Nears Key Phase 3 Ovarian Cancer Catalyst - TipRanks
Genelux (NASDAQ:GNLX) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Genelux Reports Second Quarter 2026 Results and Advances Olvi-Vec Clinical Programs in Ovarian and Lung Cancer - Quiver Quantitative
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates - Yahoo Finance
Genelux (NASDAQ:GNLX) Issues Earnings Results - MarketBeat
GENELUX Corp 6M 2026: Revenue $0 Net loss $(18.4M), EPS $(0.41) — 10-Q Summary - TradingView
Genelux (GNLX) deepens losses while funding Phase 3 cancer trial and warning on cash runway - Stock Titan
Genelux Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Genelux Corp (GNLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Genelux Corp (GNLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Genelux Corporation (GNLX) Slips 1.11% as Shares Test Support Near $2.54High Low Breadth - dars.gov.et
Insiders Sold Genelux At US$3.34, Meanwhile Stock Sits Near US$2.51 - Sahm
Genelux Corp expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Genelux (GNLX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Genelux Corp (GNLX) Balance Sheet - tradingkey.com
Genelux Corp (GNLX) Cash Flow - TradingKey
Genelux Corp (GNLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Genelux Corp (GNLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Genelux Corp (GNLX) Income Statement - TradingKey
GNLX|Genelux Corp|Price:2.890|Chg%:-0.070 - TradingKey
Genelux Corp (GNLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Genelux (NASDAQ:GNLX) Shares Down 2.4%Should You Sell? - marketbeat.com
Genelux Corp (GNLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider Shake-Up at Genelux Corp Sparks Investor Attention - TipRanks
GENELUX (NASDAQ: GNLX) director sells 12,000 shares to cover RSU tax bill - Stock Titan
[144] GENELUX Corp SEC Filing - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer - The Manila Times
Genelux says Olvi-Vec may reawaken platinum response in ovarian cancer - Stock Titan
Genelux Corp. Actuals & Estimates (NASDAQ:GNLX) - TradingView
Genelux Corporation 8-K Filing: Company Details, Nasdaq Listing, and Emerging Growth Status (June 2026) - Minichart
Genelux elects director and ratifies auditor at annual shareholder meeting - Investing.com
Genelux Corp Stock (GNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Genelux Corp Stock (GNLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Yu Yong | Chief Scientific Officer |
Aug 31 '26 |
Sale |
2.75 |
9,683 |
26,658 |
258,688 |
| Zindrick Thomas | President and CEO |
Aug 31 '26 |
Sale |
2.67 |
34,463 |
91,899 |
1,226,427 |
| Cappello Joseph | Chief Technical Officer |
Aug 04 '26 |
Sale |
2.95 |
653 |
1,924 |
328,737 |
| Zindrick Thomas | President and CEO |
Aug 04 '26 |
Sale |
2.95 |
3,023 |
8,905 |
1,260,890 |
| Yu Yong | Chief Scientific Officer |
Aug 04 '26 |
Sale |
2.94 |
653 |
1,922 |
268,371 |
| JOHN SMITHER | Director |
Jul 01 '26 |
Proposed Sale |
2.91 |
12,000 |
34,898 |
0 |
| Smither John W | Director |
Jul 01 '26 |
Sale |
2.91 |
12,000 |
34,898 |
91,403 |
| Smalling Ralph | Head of Regulatory |
Jun 03 '26 |
Sale |
2.93 |
192 |
563 |
67,611 |
| JOHNNY THOMAS | Officer |
Jun 01 '26 |
Proposed Sale |
3.05 |
10,000 |
30,500 |
0 |
| Thomas John | Director |
Jun 01 '26 |
Sale |
2.98 |
10,000 |
29,801 |
472,784 |
6.71%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):